Peptide Receptor Radionuclide Therapy for Non–Radioiodine-Avid Differentiated Thyroid Carcinoma

Jaap J.M. Teunissen, MD[1]; Dik J. Kwekkeboom, PhD[1]; Peter P.M. Kooij, MSc[1]; Willem H. Bakker, PhD[1]; and Eric P. Krenning, PhD[1,2]

[1]Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; and [2]Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands

In patients with progressive metastatic (or recurrent) differentiated thyroid carcinoma (DTC) who do not respond to radioiodine therapy or do not show uptake on radioiodine scintigraphy, treatment options are few. Because these tumors may express somatostatin receptors, peptide receptor radionuclide therapy might be effective. We evaluated the therapeutic efficacy of the radiolabeled somatostatin analog ^{177}Lu-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid^0 (DOTA), Tyr^3-octreotate (^{177}Lu-DOTATATE) in patients with DTC. The uptake of radioactivity in tumors was also studied in relation to treatment outcome. **Methods:** Five patients with DTC (3 with Hürthle cell thyroid carcinoma [HCTC], 1 with papillary thyroid carcinoma [PTC], and 1 with follicular thyroid carcinoma [FTC]) were treated with 22.4–30.1 GBq of ^{177}Lu-DOTATATE. Response to therapy was evaluated with CT. Uptake on ^{177}Lu-DOTATATE scintigraphy (24 h after treatment), expressed as percentage of injected dose, was compared with uptake on pretherapy ^{111}In-octreotide scintigraphy (24 h after injection). **Results:** After the last treatment with ^{177}Lu-DOTATATE, 1 patient with HCTC had stable disease as a maximum response, 1 patient with HCTC had minor remission (tumor shrinkage between 25% and 50%), and 1 patient with HCTC had partial remission (shrinkage ≥50%). The responses in PTC and FTC were stable disease and progressive disease, respectively. A decrease in serum thyroglobulin level was found in patients with HCTC. Patients with minor and partial remissions had the highest ^{177}Lu-DOTATATE–to–^{111}In-diethylenetriamine pentaacetic acid^0-octreotide (^{111}In-octreotide) uptake ratios (3.2 and 2.4, respectively) whereas the other patients had uptake ratios smaller than 1.5. **Conclusion:** ^{177}Lu-DOTATATE therapy can be effective in patients with progressive DTC who have no therapeutic options and sufficient uptake of ^{111}In-octreotide in tumor lesions as shown on ^{111}In-octreotide scintigraphy. This finding is especially important in patients with HCTC, because they cannot benefit from radioiodine therapy because of non–iodine-avid lesions at diagnosis.

Key Words: differentiated thyroid carcinoma; radionuclide therapy; ^{177}Lu; somatostatin receptor; octreotate

J Nucl Med 2005; 46:107S–114S

Standard therapy in patients with differentiated (follicular and papillary) thyroid carcinoma (DTC) involves total or near-total thyroidectomy, followed by ablation of the thyroid remnant with ^{131}I. Although long-term prognosis with this combination of surgery and radioiodine therapy is generally quite good, tumor recurrences occur in about 20% of patients, sometimes decades after initial therapy (1,2). Follow-up in these patients is based on a combination of serum thyroglobulin (Tg) monitoring and radioiodine whole-body scans (WBSs). Whenever recurrence or metastatic disease is evident on the WBS, patients are retreated with radioiodine. However, in 20%–30% of these patients, additional ^{131}I therapy is not effective because of the lack of radioiodine uptake in tumors (3,4). In addition, Hürthle cell thyroid carcinomas (HCTCs), which are assigned to the group of follicular thyroid carcinoma (FTC), are known to rarely take up iodine, even at the time of diagnosis (5).

Alternative treatments in patients with no uptake of radioiodine are few. Dedifferentiation is associated with a worse prognosis, which is largely because these patients cannot be treated with radioiodine (6). Patients with iodine-concentrating pulmonary metastases have a 5-y survival rate of 60% compared with 30% for patients with tumors that do not concentrate radioiodine (4,7). Therefore, any effective therapy would be welcome. As most of these patients have widespread metastatic disease, surgery is not an option. External beam radiotherapy can provide only regional control of localized recurrences. Studies on the effectiveness of chemotherapy have been disappointing (8,9).

In patients with elevated serum thyroglobulin levels with no evidence of disease on radioiodine scintigraphy, scintigraphy with the somatostatin analog ^{111}In-diethylenetriaminepentaacetic acid^0 (DTPA^0)-octreotide (^{111}In-octreotide, Octreoscan; Mallinckrodt) can be an alternative imaging modality. Several reports have demonstrated uptake of ^{111}In-octreotide in metastatic or recurrent disease in the majority of these patients (10–13). As a consequence, the use of high doses of radiolabeled somatostatin analogs

as targeted therapy in peptide receptor radionuclide therapy (PRRT) has become the focus of major interest as an alternative therapy. Patients with progressive DTC and tumor uptake on ^{111}In-octreotide scintigraphy have been treated with various radiolabeled somatostatin analogs, including ^{111}In-octreotide, ^{90}Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid[0] (DOTA)-D-Phe[1],Tyr[3]-octreotide (^{90}Y-DOTATOC), and ^{90}Y-DOTA-lanreotide (14–17). In this study, we report the results of treatment with the novel radiolabeled somatostatin analog ^{177}Lu-DOTA[0],Tyr[3]-octreotate (^{177}Lu-DOTATATE) in 5 patients with DTC.

MATERIALS AND METHODS

Patients

Five patients with recurrent or metastatic differentiated thyroid carcinoma were treated with ^{177}Lu-DOTATATE. Patient characteristics are summarized in Table 1. All patients had visible tumor uptake on ^{111}In-octreotide scintigraphy before therapy. None of the patients had been treated with other radiolabeled somatostatin analogs in the past. All patients were on thyroid-stimulating hormone (TSH) suppressive thyroxin therapy. Prerequisites for treatment were: hemoglobin ≥5.5 mmol/L; white blood cell count ≥2 × 10^9/L; platelets ≥75 × 10^9/L; creatinine ≤150 μmol/L; Karnofsky performance status ≥50. All patients gave written informed consent to participate in the study, which was approved by the medical ethical committee of the hospital.

Imaging

[111]In-octreotide. Planar spot imaging was performed with a double-head γ-camera (Prism 2000XP; Philips Medical Systems). Windows with a 20% width were centered over each of the 2 ^{111}In photon peaks (245 and 172 keV). Fifteen-minute spot images were obtained 24 h after injection of 222 MBq of ^{111}In-octreotide. A standard with a known aliquot of the injected dose was measured for dosimetry.

^{177}Lu-DOTATATE. Planar spot images of the chest, neck, and upper abdomen were obtained 24 h after injection of the therapeutic dose of ^{177}Lu-DOTATATE. Upper abdomen images were also obtained on 2 occasions in the following days for kidney dosimetry. Counts (20% window width) from the 208 keV γ-peak were collected. The acquisition time was 15 or 7.5 min/view. For dosimetry, a standard with a known aliquot of the injected dose was also measured.

Therapy

DOTATATE was obtained from Mallinckrodt. [177]LuCl$_3$ was obtained from NRG and the Missouri University Research Reactor, distributed by IDB. ^{177}Lu-DOTATATE was prepared as described in a previous publication (18). Three milligrams of granisetron were injected intravenously and an infusion of amino acids (2.5% lysine and 2.5% arginine in 1 L 0.9% NaCl at 250 mL/h) was started 30 min before administration of the radiopharmaceutical and lasting up to 3.5 h afterward. The radiopharmaceutical was coadministered through a second pump system. Treatment doses of 1.9 and 3.7 GBq were injected over 20 min and those of 5.6 GBq and 7.4 GBq were injected over 30 min. The interval between treatments varied from 6 to 15 wk. The number of treatments varied from 3 to 8. Some patients were included in the early phase of therapy with ^{177}Lu-DOTATATE, when dose escalation was among the objectives. As a result of the time schedule, completion of all treatments varied from 3 to 12 mo for any individual. All patients were allowed to receive up to a cumulative dose of 30 GBq, which corresponded to a calculated bone marrow dose of 2 Gy, except in those individual cases in which kidney dosimetry indicated less (maximum allowed kidney dose was 23 Gy).

Routine hematology, liver and kidney function tests, hormone measurements, and serum tumor markers were measured 1 wk before each therapy, as well as at follow-up visits. CT or MR imaging was performed within 3 mo before the first therapy, and

TABLE 1
Patient Characteristics

Patient	Sex	Age (y)	Tumor classification	Prior therapy	Tg (μg/mL)*	TSH (mU/L)†	[131]I/^{123}I scan‡	^{111}In-octreotide§	PD‖	Cumulative dose (GBq)	No. of treatments
1	M	52	PTC	TT, ND, RIT (16.7 GBq)¶, R	49.1	0.168	−	2	Yes	25.7	8
2	F	73	FTC	TT, RIT (10.6 GBq), R, C	5665	<0.01	−	2	Yes	22.4	3
3	F	52	HCTC	TT, ND, RIT (1.9 GBq)	1110	0.02	−	3	Yes	27.4	8
4	F	74	HCTC	TT, RIT (12.9 GBq)	126	NA	+	2	No	30.1	4
5	F	52	HCTC	TT, RIT (13.0 GBq), R	237	0.24	±	1	No	22.7	3

*Serum Tg level during levothyroxine treatment before ^{177}Lu-DOTATATE therapy.

†TSH during levothyroxine treatment.

‡Outcomes of radioiodine scan. + = positive; − = negative; ± = mixed.

§Tumor uptake score on ^{111}In-octreotide scintigraphy. 1 = uptake in lesion < uptake in liver; 2 = uptake in lesion = uptake in liver; 3 = uptake in lesion > uptake in liver (as described in [19]).

‖Documented PD within 1 y before therapy.

¶RIT, ^{131}I therapy (cumulative dose).

TT = total thyroidectomy; ND = neck dissection; R = external radiation; C = chemotherapy; NA = not available.

6–8 wk, 3 mo, and 6 mo after the last treatment. Thereafter follow-up continued every 6 mo.

In Vivo Measurements

CT- or MR-assessed tumor measurements were scored according to the following criteria: progressive disease (PD), increase in measurable tumor mass volume ≥25%; stable disease (SD), tumor mass volume increase or decrease ≤25%; minor remission (MRe), decrease of tumor mass volume between 25% and 50%; and partial remission (PR), decrease of tumor mass volume ≥50%. Time to progression (TTP) was defined as the time interval between the first treatment and the earliest date of disease progression based on CT or MR imaging measurements. The amount of uptake on pretherapy ^{111}In-octreotide and posttherapy ^{177}Lu-DOTATATE scintigraphy was scored visually on planar images on a 4-point scale according to criteria previously described by Krenning et al. (19): lower than (grade 1), equal to (grade 2), or greater than (grade 3) normal liver tissue; and grade 4, higher than normal spleen/kidney uptake.

RESULTS

Five patients with metastatic DTC (3 with HCTC, 1 with papillary thyroid carcinoma [PTC], and 1 with FTC) were treated with 22.4–30.1 GBq of ^{177}Lu-DOTATATE. The patients were either negative on ^{131}I scintigraphy after therapy or proven unresponsive to ^{131}I therapy. Metastatic disease was present in all patients based on conventional imaging (CT/MR imaging or sonography), pathologic uptake of ^{111}In-octreotide, and elevated serum Tg levels. Tumor response after therapy was monitored by CT/MR imaging and serum Tg levels (Table 2).

Patient 1 was diagnosed in 1995 with PTC with supraclavicular metastases. Initial treatment consisted of total thyroidectomy followed by radioiodine ablation. In April 1996, the patient was treated with radioiodine for recurrent disease. Because of a newly developed sarcomatoid carcinoma of the vocal chord, a total laryngectomy and bilateral nodal neck dissection was performed later that year. Lymph nodes were positive for DTC, and a third dose of ^{131}I was given. In 1998, a fourth treatment of ^{131}I was given because

of a third recurrence. However, no uptake of ^{131}I was visible on posttherapy scintigraphy. In contrast, ^{111}In-octreotide scintigraphy showed uptake in the mediastinum. Subsequently, ^{177}Lu-DOTATATE therapy was initiated. Eight treatments were given with a cumulative treatment dose of 25.7 GBq, which resulted in SD. TTP was documented 18 mo after the first treatment, with gradually increasing serum Tg levels. Thereafter, CT measurements showed PD. Four years after the first treatment, the patient died of the disease.

Patient 2 was diagnosed in 1990 with FTC. Within 1 y after total thyroidectomy and ablation, CT assessment showed lung metastases, which were treated with a therapeutic dose of [131]I. However, posttherapy ^{131}I scintigraphy did not reveal any uptake in tumor. Therefore, additional treatment consisted of local external radiotherapy and chemotherapy with adriamycin. However, the patient had PD, and her clinical condition worsened. In 2000, tumor progression led to airway obstruction, which was complicated with pneumonia and severe stridor, necessitating emergency tracheostomy. At that time, ^{111}In-octreotide scintigraphy revealed numerous lesions in the chest, and, subsequently, ^{177}Lu-DOTATATE therapy was started. Three treatments of ^{177}Lu-DOTATATE with a total dose of 22.4 GBq could not stop tumor progression, which was obvious from both symptomatology and increased serum Tg levels. Two weeks after the last therapy, the patient died of tumor progression.

Patient 3 was diagnosed with HCTC and had undergone total thyroidectomy combined with a neck dissection. However, complete removal of the tumor mass was not possible because of intraoperative identification of tumor growth into the trachea. Surgery was followed by radioiodine therapy. Eighteen months later, an ultrasound of the neck revealed continued growth of the (para)tracheal mass, which did not accumulate any [123]I. ^{111}In-octreotide scintigraphy, however, showed uptake in the lower neck region. ^{177}Lu-DOTATATE therapy was initiated, and the patient received 8 treatments with a cumulative dose of 27.4 GBq. Six months after the last therapy, the patient was found to be in MRe. Two years

TABLE 2
Results of ^{177}Lu-DOTATATE Therapy

| Patient | Tumor uptake score* | | Best response after therapy[†] | | TTP (mo)[‡] |
	Pretherapy ^{111}In-octreotide	Post ^{177}Lu-octreotate therapy	Tumor volume	Tg	
1	2	1	SD	Increase	18
2	2	3	PD	Increase	4
3	3	3	MRe	Decrease	43
4	2	2	SD	Decrease	24+
5	1	3	PR	Decrease	22+

*Tumor uptake score according to SSTR scintigraphy visual scoring system as described previously (19).

[†]SD = <25% reduction or increase in tumor size; PD = >25% increase in tumor size; MRe = between 25% and 50% reduction in tumor size; PR = >50% reduction in tumor size.

[‡]TTP = number of months since start of therapy.

later progression was demonstrated. After an initial rise in serum Tg level after treatment, this decreased to a nadir of 46.6 μg/L, which reflected decrease of tumor mass volume (Fig. 1A).

Patient 4 initially had a left-sided hemithyroidectomy for HCTC. Sixteen years later, 3 lung metastases were detected, and she had a right-sided hemithyroidectomy followed by ^{131}I therapy with 3.7 GBq, after which the serum Tg levels decreased from 150 to 18 μg/L. However, no change in tumor size was found. One year later no accumulation during ^{123}I scintigraphy was found. Despite the absence of radioiodine uptake, she was retreated with 3.7 GBq of ^{131}I, with no effect on tumor mass or serum Tg levels. In 1999, the serum Tg level increased to 507 μg/L and 5.5 GBq of ^{131}I was administered. Despite a positive lesion in the right upper lobe of the lung on ^{131}I scintigraphy after therapy, again no effect was found. Because of positive lesions detected on ^{111}In-octreotide scintigraphy, the patient received 4 treatments with a total dose of 30.1 GBq ^{177}Lu-DOTATATE. The serum Tg levels, which were measured before each treatment, increased up to a maximum of 1,730

μg/L. After the last treatment, the serum Tg levels decreased, with a nadir of 746 μg/L 14 mo later (Fig. 1B). On CT, no difference in tumor size was found. However, the radiology report mentioned an inhomogeneous aspect that suggested tumor necrosis.

Patient 5 with an HCTC was diagnosed in 1997 and subsequently underwent a total thyroidectomy followed by radioiodine ablation therapy. Because of local recurrences in the surgical bed and low cervical region, she was retreated with radioiodine in 2000 and 2001. Persistent uptake near the jugulum was seen on ^{131}I scintigraphy after therapy. In 2001, additional imaging was performed because of persistent elevated serum Tg levels and progressive pain in the left leg. In addition to the neck lesion seen on ^{131}I scintigraphy, both ^{18}F-FDG PET and MRI showed lesions in the spine (L3 and L5-S1). Lack of radioiodine accumulation in the latter lesions suggested dedifferentiation, and, therefore, external radiation was given. Because of the growth of the neck lesion, which compressed the trachea, the patient developed a stridor. ^{111}In-octreotide scintigraphy showed uptake in all tumor lesions as previously seen on ^{18}F-FDG


FIGURE 1. Time course of serum Tg and TSH levels in patient 3, 4, and 5 treated with ^{177}Lu-DOTATATE. Broken lines represent pretherapy levels.

PET and MRI. The patient received 3 treatments with a cumulative dose of 22.7 GBq of ^{177}Lu-DOTATATE. After the second treatment, serum Tg levels began to decrease (Fig. 1C). At the same time, the CT scan showed regression of the tracheal lesion with a shrinkage of 50% 12 mo after the last therapy.

A comparison between pretherapy ^{111}In-octreotide and posttherapy ^{177}Lu-DOTATATE scintigraphy in patients 1 and 3 is shown in Figure 2. In patient 1, the uptake of both somatostatin analogs was about the same. In contrast, more uptake was shown in the tracheal lesion of patient 3 on ^{177}Lu-DOTATATE scintigraphy than on ^{111}In-octreotide scintigraphy. Calculated ^{177}Lu-DOTATATE/^{111}In-octreotide tumor uptake ratios in the tumor lesions of all patients varied from 1.1 to 3.2. Two patients with HCTC, in whom tumor shrinkage was demonstrated, had the highest ratios (Fig. 3).

DISCUSSION

Therapeutic options in patients with recurrent or metastatic DTC that cannot concentrate radioiodine are limited. Also, the loss of iodine-trapping ability, or dedifferentiation, is associated with a more aggressive behavior (6).

In this paper we describe the results of therapy with ^{177}Lu-DOTATATE in 5 patients with DTC, who had no other treatment available. CT-assessed tumor shrinkage was found in 2 patients with HCTC. Concomitantly, a decrease in serum Tg levels was observed in both patients. In the other patient with HCTC the serum Tg levels decreased significantly, whereas CT-assessed tumor volume did not change. However, the aspect of the lesions changed, which suggested necrosis. Disease stabilization was achieved in one patient with clearly progressive PTC before therapy,


FIGURE 3. Ratios of ^{177}Lu-DOTATATE and ^{111}In-octreotide uptake in tumor sites. Uptake was expressed as percentage of administered dose. Note differences in uptake between patients with HCTC who responded with MRe and PR and those who did not respond with tumor shrinkage.

whereas the patient with FTC progressed despite treatment. These results suggest that in some patients with DTC, who have no treatment options left, ^{177}Lu-DOTATATE therapy can be effective.

The reason to treat these patients with ^{177}Lu-DOTATATE, was found in the successful treatment with this compound in patients with somatostatin receptor–positive gastroenteropancreatic (GEP) tumors. Objective tumor shrinkage was demonstrated in up to 38% of patients (20). In addition, reports in which other somatostatin analogs were labeled with different radionuclides, such as ^{111}In or ^{90}Y, showed similar therapeutic benefit in patients with GEP tumors (16,17,21,22). Apart from GEP tumors, other results of therapy in patients with DTC were reported (Table 3). Patients with DTC were treated because they had progressive disease, somatostatin receptor–positive lesions on ^{111}In-octreotide scintigraphy, and no other treatment option available.

Krenning et al. (19) reported the first 2 DTC patients treated with radiolabeled somatostatin analogs. Both had PTC and were treated with ^{111}In-octreotide, which was available for therapy. One patient, who had a total cumulative dose of at least 20 GBq, showed disease stabilization, whereas the other patient, who had received <20 GBq, was lost to follow-up. In a review that summarized the use of ^{111}In-octreotide therapy in a total of 50 patients in a single institution, 40 patients were evaluated after cumulative doses of at least 20 GBq up to 160 GBq. Within this group, 5 patients had DTC, including 4 patients with PTC and 1 with FTC (17). Four patients were progressive despite treatment, whereas 1 patient, who was reported earlier to have SD for some time, ultimately

FIGURE 2. Images comparing pretherapy ^{111}In-octreotide scintigraphy (A) and posttherapy ^{177}Lu-DOTATATE scintigraphy at 24 h (B). Top row shows corresponding images of tumor sites in patient 1 with metastatic PTC. Bottom row shows corresponding images of patient 3 with HCTC.

TABLE 3
Peptide Receptor Radionuclide Therapy in 58 Patients With Differentiated Thyroid Carcinoma

References	Tumor classification	Radiopharmaceutical			Cumulative dose	Response (TTP [mo])	Criteria*
		Radionuclide	Chelator	Peptide			
Gorges et al., 2001 (14)	3 × HCTC	^{90}Y	DOTA		1.7–9.6 GBq	1 × SD (21), 2 × PD	NA
Waldherr et al., 2001 (15)	3 × FTC; 4 × PTC; 1 × ATC	^{90}Y	DOTA		1.7–14.8 GBq	2 × SD (8,8); 6 × PD	WHO
Virgolini et al., 2002 (16)	25 × TC	^{90}Y	DOTA	Lanreotide	0.9–7.0 GBq	3 × RD (NA), 11 × SD (NA), 11 × PD	WHO
Valkema et al., 2002 (17)	1 × FTC; 4 × PTC	^{111}In	DTPA	Octreotide	3.0–8.3 GBq	4 × PD; 1 × SD	SWOG
Chinol et al., 2002 (21)	2 × PTC	^{90}Y	DOTA		>7.4 GBq		SWOG
Christian et al., 2003 (12)	1 × HCTC	^{90}Y	DOTA				NA
Gabriel et al., 2004 (24)	4 × FTC; 1 × PTC	^{90}Y	DOTA		5.6–7.4 GBq	5 × SD (5)	NA
Stokkel et al., 2004 (23)	4 × FTC; 5 × PTC	^{111}In	DTPA	Octreotide	14.3–33.1 GBq	4 × SD; 5 × PD	NA

*WHO = World Health Organization criteria: regressive disease = >25% reduction in tumor size; SD = <25% reduction or increase in tumor size; PD = >25% increase in tumor size. SWOG = Southwest Oncology Group criteria of tumor response: PR = >50% reduction in tumor size; SD = ±25% reduction or increase in tumor size; PD = >25% increase in tumor size.

TC = undefined thyroid cancer; ATC = anaplastic thyroid carcinoma; NA = not available.

progressed. In a recent report, 11 patients with progressive iodine nonresponsive thyroid carcinoma were treated with high, fixed doses of ^{111}In-octreotide (23). Nine patients were evaluable, because 2 patients died during follow-up of causes unrelated to their disease. Six months after the last therapy, 4 patients had SD and 5 patients had PD. Stablilization of disease was accompanied with a stable Tg level, whereas 3 out of a group of 5 patients with radiologic progression had increasing levels of Tg. Interestingly, the mean Tg value in the latter group was higher than in the group with stabilization of disease (mean Tg value 180,432 vs. 275 μg/L). It was suggested that low Tg values could be used as selection criteria for ^{111}In-octreotide therapy.

Waldherr et al. (15) treated 8 DTC patients (3 FTC, 4 PTC, and 1 anaplastic thyroid carcinoma) with ^{90}Y-DOTATOC. Two patients, who were treated with 9.1 and 14.8 GBq, had SD and documented TTP of 8 mo, whereas the other patients had PD. Chinol et al. (21) also used ^{90}Y-DOTATOC to treat 2 patients with PTC. Unfortunately, the efficacy of therapy in these 2 patients was difficult to determine from this study, because results were presented as the effect of treatment in the whole group of somatostatin receptor (SSTR) positive tumors. In the Multicenter Analysis of a Universal Receptor Imaging and Treatment Initiative, a European Study (MAURITIUS) trial reported by Virgolini et al. (16), 25 patients with radioiodine negative thyroid carcinoma were treated with 0.9–7.0 GBq of the somatostatin analog ^{90}Y-DOTALAN. Three patients had regressive disease (>25% reduction of tumor size), 11 had SD, and 11 had PD. In a very recent report, 5 patients with DTC were

treated with ^{90}Y-DOTATOC with a dose range of 5.6 GBq to 7.4 GBq (24). The authors reported that patients who responded under this therapy regimen had SD for at least 5 mo. Especially interesting in comparison with our results is the report by Gorges et al. (14), who described the courses of disease of the first 3 patients with HCTC treated with ^{90}Y-DOTATOC (total dose, 1.7–9.6 GBq). The patient with the highest dose responded with a period of SD of 9 mo, whereas the other 2 patients had progressive disease despite treatment. They concluded that the protocol was not ideal, because tumor radiation dose was suboptimal.

To draw conclusions from all the studies concerning the therapeutic efficacy of PRRT in patients with non–radioiodine-avid or unresponsive thyroid cancer is difficult. The number of treated patients in the reported studies was low. Furthermore, different radiolabeled somatostatin analogs were used with individually variable administered doses. Clearly, PRRT in DTC seems to be less effective than in GEP neuroendocrine tumors.

One reason for this difference in efficacy might be the expression profile of SSTR subtypes by tumors. Reubi et al. (25), who intensively studied the SSTR subtype profile of numerous human tumors, reported a predominance of SSTR2 or SSTR1 in GEP tumors. In contrast, in vitro studies with thyroid cancer cell line monolayers and xenografts showed a predominant expression of SSTR3 and SSTR5, whereas SSTR2 mRNA was only faintly detectable (26). In another report, in which the receptor subtype expression in biopsied DTC tumor tissue was investigated by Northern Blot analyses, SSTR1, SSTR3, SSTR4, and SSTR5 were expressed in all tumors, whereas SSTR2 was

not detected in any FTC or PTC tumors. In line with these observations, Forssell-Aronsson et al. (27) also demonstrated that the highest tumor-to-background ratio and expression of high-affinity SSTR2, was found in medullary thyroid carcinoma and Hürthle cell neoplasia. In the latter, the expression of SSTR2 was irregular. These findings suggest that the SSTR subtype expression profile found in DTC cells is different and more variable than that in GEP tumors.

Most radiolabeled somatostatin analogs available for therapy share the high binding affinity for the SSTR2 receptor. It was reported that, in comparison with $DTPA^0,Tyr^3$-octreotide, $DTPA^0,Tyr^3$-octreotate showed improved binding to SSTR-positive tissues in animal experiments (28). Furthermore, the somatostatin analog DOTATATE has a 9-fold higher affinity for the SSTR2 than does DOTATOC, whereas the affinity to SSTR3 and SSTR5 were found to be lower (29). In line with the higher affinity for the SSTR2, our biodistribution studies on ^{111}In-octreotide and ^{177}Lu-DOTATATE scintigraphy, reported previously, showed a 3- to 4-fold higher tumor uptake in 4 out of 5 patients (18). The presence of SSTR subtypes other than SSTR2 was suggested as an explanation for equivalent tumor uptake of both somatostatin analogs in 1 patient with PTC, who is also described in this article (patient 1). Interestingly, the ^{177}Lu-DOTATATE/^{111}In-octreotide uptake ratios calculated in the 5 patients demonstrated that the 2 HCTC patients with the highest uptake ratios responded with tumor shrinkage, whereas the others had ratios <1.5. Thus, in patients with PTC or FTC with tumors that probably exhibit a different and variable SSTR expression profile with predominantly SSTR5 and SSTR3 instead of SSTR2, there is no clear advantage of Tyr^3-octreotate over Tyr^3-octreotide.

For the better tumor targeting and increase in uptake required for better therapeutic efficacy of PRRT in DTC, SSTR subtype-specific analogs with higher affinity for SSTR3 and SSTR5 are necessary. Most promising is the recent study by Wild et al. (30), who reported the first preclinical data on ^{111}In- and ^{90}Y-labeled DOTA-1-Nal^3-octreotide (DOTA-NOC), which has, apart from high affinity to SSTR2, a favorable affinity for SSTR3 and SSTR5. In addition, they briefly mentioned excellent images of thyroid cancer patients in clinical studies with [^{111}In]DOTA-NOC. It was assumed that DOTA-NOC labeled with either ^{90}Y or ^{177}Lu will have similar favorable properties, so that it might become available for therapy in patients with DTC in the near future.

In our opinion, the best candidates for PRRT with ^{177}Lu-DOTATATE in non–iodine-avid metastatic and radioiodine unresponsive DTC are patients with HCTC. The combination of a large percentage of HCTC patients with positive lesions on ^{111}In-octreotide scintigraphy, relatively high tumor uptake of ^{177}Lu-DOTATATE com-pared with PTC or FTC, and the favorable outcomes observed in our patients suggest that especially in these patients ^{177}Lu-DOTATATE may induce tumor shrinkage or prolonged disease stabilization.

REFERENCES

1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med.* 1994;97:418–428.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. *N Engl J Med.* 1998;338:297–306.
3. Cooper DS, Schneyer CR. Follicular and Hurthle cell carcinoma of the thyroid. *Endocrinol Metab Clin North Am.* 1990;19:577–591.
4. Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. *Endocrinol Metab Clin North Am.* 1990;19:685–718.
5. Caplan RH, Abellera RM, Kisken WA. Hurthle cell neoplasms of the thyroid gland: reassessment of functional capacity. *Thyroid.* 1994;4:243–248.
6. Sherman SI. Thyroid carcinoma. *Lancet.* 2003;361:501–511.
7. Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. *Cancer.* 1996;78:2184–2192.
8. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. *Cancer.* 1985;56:2155–2160.
9. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. *Tumori.* 1990;76:480–483.
10. Postema PT, De Herder WW, Reubi JC, et al. Somatostatin receptor scintigraphy in non-medullary thyroid cancer. *Digestion.* 1996;57(suppl 1):36–37.
11. Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. *J Endocrinol Invest.* 2001;24:415–422.
12. Christian JA, Cook GJ, Harmer C. Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid. *Br J Cancer.* 2003;89:258–261.
13. Stokkel MP, Reigman HI, Verkooijen RB, Smit JW. Indium-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. *J Cancer Res Clin Oncol.* 2003;129:287–294.
14. Gorges R, Kahaly G, Muller-Brand J, Macke H, Roser HW, Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. *Thyroid.* 2001;11:647–659.
15. Waldherr C, Schumacher T, Pless M, et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [^{90}Y]-DOTA-D-Phe^1-Tyr^3-octreotide: a pilot study. *Nucl Med Commun.* 2001;22:673–678.
16. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. *Semin Nucl Med.* 2002;32:148–155.
17. Valkema R, De Jong M, Bakker WH, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. *Semin Nucl Med.* 2002;32:110–122.
18. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [^{177}Lu-DOTA^{0}Tyr^3]octreotate: comparison with [^{111}In-DTPA^0]octreotide in patients. 2001;28:1319–1325.
19. Krenning EP, de Jong M, Kooij PP, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. *Ann Oncol.* 1999;10(suppl 2);S23–S29.
20. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. *Eur J Nucl Med Mol Imaging.* 2003;30:417–422.

21. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. *Semin Nucl Med.* 2002;32:141–147.

22. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq ^{90}Y-DOTATOC. *J Nucl Med.* 2002;43:610–616.

23. Stokkel MP, Verkooijen RB, Bouwsma H, Smit JW. Six month follow-up after ^{111}In-DTPA-octreotide therapy in patients with progressive radioiodine nonresponsive thyroid cancer: a pilot study. *Nucl Med Commun.* 2004;25:683–690.

24. Gabriel M, Froehlich F, Decristoforo C, et al. ^{99m}Tc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. *Eur J Nucl Med Mol Imaging.* 2004;31:330–341.

25. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. *Eur J Nucl Med.* 2001;28:836–846.

26. Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. *J Clin Endocrinol Metab.* 1997;82:1857–1862.

27. Forssell-Aronsson EB, Nilsson O, Bejegard SA, et al. ^{111}In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors. *J Nucl Med.* 2000;41:636–642.

28. de Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. *Cancer Res.* 1998;58:437–441.

29. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. *Eur J Nucl Med.* 2000;27:273–282.

30. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. *Eur J Nucl Med Mol Imaging.* 2003;30:1338–1347.